RTNX.F Stock Overview
Develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Renalytix Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.16 |
| 52 Week High | UK£0.64 |
| 52 Week Low | UK£0.15 |
| Beta | 2.07 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -98.42% |
| 5 Year Change | -96.33% |
| Change since IPO | -93.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| RTNX.F | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 0% | 7.9% | 1.6% |
| 1Y | n/a | 16.0% | 32.3% |
Return vs Industry: Insufficient data to determine how RTNX.F performed against the US Healthcare Services industry.
Return vs Market: Insufficient data to determine how RTNX.F performed against the US Market.
Price Volatility
| RTNX.F volatility | |
|---|---|
| RTNX.F Average Weekly Movement | n/a |
| Healthcare Services Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RTNX.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine RTNX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | James McCullough | renalytix.com |
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Renalytix Plc Fundamentals Summary
| RTNX.F fundamental statistics | |
|---|---|
| Market cap | US$30.41m |
| Earnings (TTM) | -US$28.03m |
| Revenue (TTM) | US$2.35m |
12.9x
P/S Ratio-1.1x
P/E RatioIs RTNX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RTNX.F income statement (TTM) | |
|---|---|
| Revenue | US$2.35m |
| Cost of Revenue | US$2.05m |
| Gross Profit | US$299.00k |
| Other Expenses | US$28.33m |
| Earnings | -US$28.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.085 |
| Gross Margin | 12.71% |
| Net Profit Margin | -1,191.75% |
| Debt/Equity Ratio | -72.8% |
How did RTNX.F perform over the long term?
See historical performance and comparison